Kcnj2 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
{{infobox gene
| name = Potassium Inwardly Rectifying Channel Subfamily J Member 2
| symbol = KCNJ2
| chromosomal_location = 17q24.3
| ncbi_gene_id = 3760
| ensembl_id = ENSG00000123784
| uniprot_id = P48745
| omim_id = 600681
| associated_diseases = Andersen-Tawil Syndrome, Short QT Syndrome, Atrial Fibrillation, Alzheimer's Disease, Parkinson's Disease
}}
KCNJ2 encodes Kir2.1, a member of the inward rectifier potassium channel family. These channels play critical roles in maintaining resting membrane potential and controlling cellular excitability in neurons and cardiac myocytes.
Kir2.1 is an inward rectifier potassium channel with distinctive properties:
- Channel Type: Inward rectifier potassium channel (Kir2.1)
- Primary Structure: Two transmembrane domains with intracellular N- and C-termini
- Biophysical Properties: Strong inward rectification, conduct K+ preferentially in inward direction
- Subcellular Localization: Somatodendritic compartment, dendritic spines, cardiac myocytes
- Resting Membrane Potential: Major contributor to neuronal resting membrane potential (-70 to -90 mV)
- Repolarization: Helps terminate action potentials
- Cellular Excitability: Regulates input resistance and firing properties
- Dendritic Integration: Influences synaptic integration in dendrites
¶ Andersen-Tawil Syndrome (ATS)
- Causative gene for ATS type 1
- Loss-of-function mutations reduce Kir2.1 current
- Characterized by periodic paralysis, cardiac arrhythmias, developmental abnormalities
- Short QT syndrome: Gain-of-function variants
- Atrial fibrillation: Associated variants
- Long QT syndrome: Some variants
- Altered Kir2.1 function affects neuronal potassium homeostasis
- May contribute to membrane potential dysregulation in AD neurons
- Therapeutic target for improving neuronal excitability
- Kir2.1 channels regulate dopaminergic neuron function
- Altered expression in substantia nigra in PD models
- Target for neuroprotective strategies
- Brain: Widespread expression, highest in cortex, hippocampus, basal ganglia
- Heart: Cardiac ventricles and atria
- Skeletal Muscle: High expression
- Other Tissues: Pancreas, uterus
- Activators: No specific Kir2.1 activators approved; research compounds in development
- Inhibitors: Barium chloride (Ba2+), cesium chloride (Cs+) - research use only
- Gene therapy: Potential for dominant-negative approaches
- Plaster NM, et al. (2001). Mutations in KCNJ2 cause Andersen-Tawil syndrome. Cell.
- Lopatin AN, et al. (2001). Molecular basis of inward rectification. Annu Rev Physiol.
- Niehusmann P, et al. (2019). Kir2.1 dysfunction in Alzheimer's disease. Brain.
The study of Kcnj2 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Plaster NM, et al. (2001). Mutations in KCNJ2 cause Andersen-Tawil syndrome. Cell.
[2] Lopatin AN, et al. (2001). Molecular basis of inward rectification. Annu Rev Physiol.
[3] Niehusmann P, et al. (2019). Kir2.1 dysfunction in Alzheimer's disease. Brain.
Kir2.x channels are tetramers, each subunit containing:
- Two transmembrane helices (M1 and M2)
- P-loop between helices forming the selectivity filter
- Cytoplasmic N- and C-termini (forming most of the channel mass)
¶ Gating and Conductance
- Inward rectification: Conducts better inward (into cell) than outward
- Block by polyamines: Intracellular Mg2+ and polyamines block outward current
- Pore architecture: Highly conserved selectivity sequence (GYG) for K+ selectivity
- PIP2 is essential for Kir channel function
- PIP2 depletion contributes to disease states
- Regulation by G-proteins and receptor tyrosine kinases
| Drug |
Condition |
Mechanism |
| Various K+ channel openers |
Under development |
Activate Kir channels |
| DIDS |
Research use |
Block inward rectification |
- Gene therapy: Viral delivery of KCNJ2
- Small molecule modulators: PIP2 pathway targeting
- ASO therapy: For specific mutations
- Kcnj2 knockout mice: Show cardiac defects, embryonic lethal
- Dominant-negative: Cardiac long QT phenotype
- Transgenic expression: Neuronal excitability changes
- Understanding tissue-specific regulation
- Developing selective modulators
- Gene therapy for channelopathies